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INTRODUCTION 
Hypertension or elevated blood pressure is one of the 
leading causes of morbidity and mortality in developed as 
well as the developing nations. Often known as the 
‘Silent Killer’, it is one of the risk factors for 
cardiovascular diseases and chronic kidney diseases, this 
making it one of the serious health problems of today’s 
world.
1
  
Hypertension as a risk factor for cardiovascular disease 
accounts for 20-50% of the morbidity and mortality.
2
 
Hypertension is the cause of 4.5% of morbidity and 5.8% 
of mortality 1.9% of the years of life lost and 1.4% 
disability adjusted life years throughout the world.
3
 
Hypertension is reported to be responsible for 57% deaths 
caused due to stroke and 24% due to coronary heart 
disease in India.
4
 
Apart from risk for CVD, hypertension also can affect the 
kidneys, brain, peripheral circulation and eyes.
5
 The 
mechanism of such wide spread complications is due to 
the damage to the vascular endothelium in the blood 
vessels.
6
 Renal hypertension puts a lot of pressure on the 
kidney leading to hypertensive nephropathy, thereby 
causing damage to the kidney. This is one of the leading 
causes of death in the elderly. Other complications which 
are often associated with hypertensive nephropathy 
include glomerular damage resulting in proteinuria and 
haematuria.
7
 Many adverse outcomes are associated with 
hypertension, including progressive loss of kidney 
function leading to kidney failure, early development and 
accelerated progression of CVD and premature death.
8
 
ABSTRACT 
 
Background: Hypertension or elevated blood pressure is one of the leading causes of morbidity and mortality. Hs-
CRP, which is a known marker for CVD, is also one of the predictive markers of inflammation processes which result 
in hypertension. Increased RDW is also believed to be associated with CVD morbidity and mortality in patients with 
previous myocardial infarction, brain vascular disease, strokes, septicemia, chronic obstructive pulmonary disease and 
hepatitis B.  
Methods: 200 patients 100 male and 100 females and 50 each of controls were selected for the study. Complete 
demographic details were collected from all the patients including the age, sex, height, weight, BMI, smoking/non-
smoking status, alcoholism etc. After a thorough clinical examination, venous blood was collected from all the 
patients after an overnight fast for lipid profile, hs-CRP and complete blood count.  
Results: The patients in both males and females had a higher BMI than that of the controls. Hs-CRP levels in males 
was 1.64 mg/L and in females it was 1.47 mg/L. Significant difference was seen in the RDW values also in the 
patients. 
Conclusions: Hs-CRP levels and RDW levels are both equally effective as a predictive marker for hypertension.  
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C-reactive protein is a member of the pentaxin family, 
having characteristic circular pentameric disc shaped 
proteins. It is normally synthesized in the liver thorough 
the influence of cytokines particularly Interleukin-6 
(IL6), secreted from the inflamed tissue.
9 
Hs-CRP is said 
to be a nonspecific marker for inflammatory response and 
it is emerging as an independent marker of CVD. 
Normally, it is present in low levels in the serum, but an 
acute inflammatory reaction can increase the levels of hs-
CRP to several folds in the serum.
9 
Apart from CVD, it is 
also one of the predictive markers of inflammation 
processes which result in hypertension.
8 
Red blood cell distribution width (RDW) is a numerical 
measure of the size variability of circulating erythrocytes 
and is routinely reported as a component of complete 
blood count in the differential diagnosis of anemia.
10
 
RDW in recent studies has been reported to be strongly 
associated with and an independent predictor of adverse 
outcomes in the general population.
11
 Increased RDW is 
also believed to be associated with CVD morbidity and 
mortality in patients with previous myocardial 
infarction.
12
  brain vascular disease, strokes, septicemia, 
chronic obstructive pulmonary disease and hepatitis 
B.
13,14
 
The specific mechanism of action of RDW remains 
unclear. There have been a few studies who have reported 
that inflammatory status is significantly related to 
ineffective erythropoiesis and that inflammatory 
cytokines, such as interleukin (IL)-1 β, IL-6, tumor 
necrosis factor (TNF)-α, desensitize bone marrow 
elytroid progenitors to erythropoiesis, inhibit red blood 
cell maturation and thereby promote anysocytosis. 
Elevated RDW may be due to an underlying 
inflammatory state.
15
  
Though there are many studies on RDW and hs-CRP as 
markers for inflammation, there are not many studies 
assessing the association of both these markers in 
hypertensive patients. Therefore this study was conducted 
to evaluate the association between RDW and hs-CRP 
and hypertension. 
METHODS 
This study was performed in the Department of Medicine 
at Deccan College of Medical Sciences Over a period of 
3 years. A total of 300 patients were included in the study 
out of which 150 were males and 150 were females, all 
below the age of 70 years. 100 patients out of the 150 
were hypertensive and 50 were normotensive and were 
considered as controls. Patients with diabetes mellitus 
and other hematological system diseases or any other 
diseases that could affect the white blood, red blood or 
hemoglobin count were excluded from the study. 
After obtaining the clearance from the Institutional 
Ethical Committee and Informed consent from the 
patients, complete demographic details were collected 
including the age, sex, height, weight, BMI, 
smoking/nonsmoking status, alcoholism etc. All the 
patients were subjected to thorough clinical examination. 
Venous blood was collected from all the patients after an 
overnight fast in K3 EDTA tubes and plain tubes and sent 
to the laboratory. From the EDTA tubes, complete blood 
count including parameters such as red cell distribution 
width (RDW), hemoglobin level, white blood corpuscles 
count, mean corpuscular volume was performed. 
Erythrocyte sedimentation rate was also done for all the 
samples. The serum was collected from the clotted blood 
in the plain tubes and subjected to various biochemical 
tests including hs-CRP, total cholesterol, high density 
lipoprotein-cholesterol, low density lipoprotein-
cholesterol, triglyceride levels.  
Statistical analysis was calculated as mean±SD. 
RESULTS 
 
Table 1: General variables of the patients and controls. 
Variables Males Females 
Patients (n=100) Controls (n=50) Patients (n=100) Controls (n=50) 
Age (years) 59.8±0.7 55.4±5.1 57.3±3.9 55.7±3.1 
Weight ( in kg) 81.2±4.1 74.2±1.9 67.2±5.1 59.1±3.1 
BMI  
<25 
≥25 
 
43 
57 
 
39 
11* 
 
39 
61 
 
41 
09* 
Systolic BP 137±5 111±3* 138±5 107±4* 
Diastolic BP 91±2  77±4* 93±4 75±4* 
Smoking  
Never 
Occasionally 
Regularly 
 
22 
49 
29 
 
24 
21 
05 
 
91 
09 
00 
 
49 
01 
00 
Alcoholism (yes/no) 
Never 
Occasionally 
Regularly 
 
24 
55 
21 
 
28 
17 
05 
 
93 
07 
00 
 
50 
00 
00 
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300 patients, 150 males and 150 females were included in 
the study. Out of 150 in each group, 50 were controls, 
with no known hypertension and no elevated blood 
pressure on the routine check prior to the study. 100 were 
hypertensive patients, either known or newly diagnosed. 
The patients in both males and females had a higher BMI 
than that of the controls (Table 1).  
Among the blood investigations, significant difference 
was observed in the triglyceride levels of the patients in 
both males and females which were considerably higher 
than the controls. The erythrocyte sedimentation rate was 
considerably higher in the patients as was the hs-CRP 
levels. Hs-CRP levels in males was 1.64 mg/L and in 
females it was 1.47 mg/L. Significant difference was seen 
in the RDW values also in the patients (Table 2).
 
Table: 2: Clinical parameters among the patients and controls. 
Variables Males Females 
 Patients Controls  Patients Controls  
Total cholesterol (mg/dL) 236.7±6.2  196.9±6.2  221.9±4.6 192.3±4.1 
HDL-cholesterol (mg/dL) 42.8±4.2 51.3±5.2 40.5±4.1 49.3±4.2 
LDL-cholesterol (mg/dL) 161.1±4.1 99.2±1.9 117.4±3.9 86.3±3.2 
Triglycerides (mg/dL) 201.5±4.3  132.9±5.1* 215±6.2 123.3±6.1* 
Fasting plasma glucose (mg/dL) 116.1±7.1 98±7.2 122.7±4.1 88.4±6.2 
Hb (g%) 13.4±0.9 12.1±0.3 12.9±0.4 11.1±0.6 
ESR (mm/h) 31.7±1.4 11.4±0.7* 36.4±2.1 12.1±2.2* 
RDW (%) 14.7±0.4 12.9±1.4 13.9±0.5 12.6±0.8* 
hs-CRP (mg/L) 1.64±0.09 0.62±0.12* 1.47±1.01 0.55±0.1* 
 *p<0.001 
DISCUSSION 
Hypertension can damage the blood vessels throughout 
the body resulting in endothelial dysfunction and vascular 
damage. Hs-CRP levels may serve as a screening test for 
the development of CVD
16,17
.  
In our study, though none of the patients had a 
cardiovascular disease, some of them had significantly 
high levels of hs-CRP, showing that they were at risk for 
CVD. The hs-CRP was 1.64 mg/l in who reported a hs-
CRP levels of 1.68 mg/l and 1 mg/l in males and females 
respectively males and 1.47 mg/L in females. This was in 
accordance to a similar study by Jithesh et al.
18
   
RDW is routinely reported in the laboratories for 
identifying the size of circulating red blood cell 
(anisocytosis) and diagnosing certain anemias, especially 
those that are microcytic caused due to iron deficiency or 
vitamin B12 deficiency or Folic acid deficiency. An 
increased RDW can also result from conditions that 
modify the shape of red blood cells due to the premature 
release of immature cells into the bloodstream (severe 
blood loss), abnormal hemoglobins (eg, sickle cell 
anemia), hemolysis or hemolytic anemias.
19,20
 
In recent times, there is evidence of a strong association 
between elevated RDW and the occurrence of chronic 
heart failure, as well as fatal and nonfatal cardiovascular 
disease events. This has resulted in RDW becoming a 
new prospective markers for predicting the outcomes of 
CVD. As it is routinely done in the laboratory, there is no 
extra cost incurred by the patient, nor is there any extra 
time lapse for treatment.
21
  
In our study we have observed a considerable raise of the 
RDW levels among the patients in comparison to the 
controls. The elevation was more prominent in males 
than in females. This was observed by Jithesh et al in 
their study as well as by Wen et al.
22
 
Since both these markers are associated with 
inflammation, it can be concluded that hypertension is 
also associated with inflammation, thereby causing CVD 
or CKD. 
CONCLUSION 
It is observed that hs-CRP levels and RDW levels are 
both equally effective as a predictive marker for 
hypertension. This can be done routinely and easily in the 
laboratories, thereby giving the clinician a good 
supportive tool for diagnosing and preventing an adverse 
outcome. 
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